Skip to main content
TipRanks
Go Ultimate75% OFF

Karyopharm Therapeutics (KPTI) Stock Price & Analysis

3 Followers

KPTI Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 483.43K
Enterprise Value
CHF 473.81M
Total Cash (Recent Filing)
CHF 65.11M
Total Debt (Recent Filing)
CHF 215.88M
Price to Earnings (P/E)
0.0
Beta
N/A
Next Earnings
Feb 10, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Regulatory Progress

Strong Phase III efficacy and constructive FDA feedback support a potentially meaningful expansion of selinexor into myelofibrosis. An on-track sNDA could broaden the commercial franchise, strengthen the company’s clinical position, and create a durable growth opportunity if approval follows.

Established Commercial Platform

Existing XPOVIO sales, an experienced hematology platform, patient support infrastructure, and reaffirmed guidance provide a commercial foundation while pipeline programs advance. Stable product revenue can support market access and launch preparation, even before any new indication contributes materially.

Operating Expense Discipline

Lower R&D and SG&A spending indicates management is prioritizing higher-value programs and improving underlying operating efficiency. If maintained, this discipline can extend the usefulness of existing resources, reduce avoidable cash consumption, and focus investment on the most valuable growth opportunities.

Bears Say

Stressed Balance Sheet And Financing Dependence

Deeply negative equity and debt that is large relative to the asset base leave limited financial flexibility. The capital structure increases dependence on refinancing, new funding, or other strategic transactions, while potential dilution or restrictive financing terms could weigh on future shareholder value.

Persistent Cash Burn And Large Losses

The business is not yet self-funding, with ongoing operating cash outflows and substantial net losses despite some improvement in burn. Continued cash consumption can constrain investment in the pipeline and make the company increasingly dependent on financing until revenue growth or profitability improves.

Pipeline Concentration And Approval Uncertainty

The failed endometrial cancer study reduces diversification across the development pipeline and places greater importance on myelofibrosis execution. Even with encouraging SENTRY results, approval and long-term label confirmation depend on regulatory review and future overall survival evidence.

Karyopharm Therapeutics News

KPTI FAQ

What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is CHF483.43K.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s next earnings report is estimated for Oct 29, 2026 (not yet confirmed), which is 18 days ago.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 13, 2026. The company reported -CHF1.903 earnings per share for the quarter, missing the consensus estimate of -CHF1.126 by -CHF0.778.
Is Karyopharm Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -0.28.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -CHF1.903 in its last earnings report, missing expectations of -CHF1.126. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Hedge funds hold Karyopharm Therapeutics shares: the largest hedge-fund position in Karyopharm Therapeutics is 398,001,476 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology